6月18日，康方生物盘中上涨3.64%，报86.95港元，成交额2.18亿港元。消息面上，医药行业回购潮持续发酵，叠加创新药板块估值跌至历史低位后技术性反弹，推动股价企稳回升。
此前公司董事会批准动用最多2亿港元在公开市场购买股份，管理层拟增持合计不超过5000万港元。同期中国生物制药亦宣布不超过20亿港元购股计划，行业超百家A/H股医药公司披露回购或增持方案。多家券商指出，创新药指数已跌回上一轮行情启动前位置，板块性价比凸显。康方生物此前因ASCO依沃西HARMONi-6 OS阳性结果兑现后持续获利了结，股价较数据公布后高点累计跌幅逾30%，当前技术面超卖修复与产业资本增持信号共同支撑反弹。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.